At a glance
ClinicalIndex Comparison RecordN/ACompleted· 591 enrolled
Drug / intervention
Desloratadine (assigned by investigator as part of normal practice)drug
Likely dose
Desloratadine (assigned by investigator as part of normal practice) 2.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study Evaluating the Safety and Efficacy of Desloratadine Syrup for Perennial Allergic Rhinitis in Indonesian Pediatric Patients
In Brief
An observational study evaluating Desloratadine (assigned by investigator as part of normal practice) for Rhinitis. Completed, enrolled 591 participants.
Detailed Summary
Evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in Indonesian pediatric patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2005
Primary CompletionDec 2007
First PostedJun 2008
TodayJul 2026
First PostedJun 25, 2008
Enrollment StartMay 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.0 years ago
Interventions
Desloratadine (assigned by investigator as part of normal practice)drug
Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits